ArticleBrain, behavior, & immunity - health2026
The association between high-sensitivity C-reactive protein and depression symptom severity among U.S. adults: A multivariable analysis of NHANES data.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Systemic inflammation may play a role in depression. This study examined the association between high-sensitivity C-reactive protein (hs-CRP), a well-established biomarker of systemic inflammation, and the severity of depression symptoms as measured by the Patient Health Questionnaire (PHQ-9). Methods: Data from the National Health and Nutrition Examination Survey (NHANES) 2015-2023 were utilized. Depression was classified as low (PHQ-9 < 10) and high (PHQ-9 ≥ 10). hs-CRP levels were dichotomized into low (≤3 mg/L) and high (>3 mg/L). Logistic regression models were used to analyze the association between hs-CRP and depression symptom severity, adjusting for demographic, socioeconomic, health-related covariates, while considering the NHANES complex sampling design. Results: Among 15,525 U.S. adults, elevated hs-CRP levels were significantly associated with high depression symptom severity. hs-CRP > 3 mg/L was associated with 26% greater odds of high depression symptom severity (adjusted OR = 1.26; 95% CI: 1.04-1.51; p-value = 0.018). Other factors associated with greater odds of high depression symptom severity included female sex, younger age (20-39 years), low-income status, unmarried status, tobacco use, multimorbidity, and timing of survey responses in relation to the onset of the COVID-19 pandemic. Exploratory depression symptom-domain analysis showed that hs-CRP was significantly associated with somatic symptom-domain (p-value <0.001) while not significantly associated with cognitive/affective symptom-domain (p-value = 0.056). Conclusion: Depression symptom severity is influenced by many demographic, socioeconomic, behavioral, and health-related factors. The study findings support an independent association between elevated hs-CRP and depression symptom severity, and the significance of the association could depend on the specific depression symptom-domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.